同一患者多种oncotype DX®的比较。

IF 1.9 4区医学 Q3 OBSTETRICS & GYNECOLOGY Breast Journal Pub Date : 2021-11-01 Epub Date: 2021-09-12 DOI:10.1111/tbj.14288

Ashley D Marumoto, Srivarshini C Mohan, Stephanie A K Angarita, Marissa K Srour, Vicky E Norton, Farnaz Dadmanesh, Armando E Giuliano

{"title":"同一患者多种oncotype DX®的比较。","authors":"Ashley D Marumoto, Srivarshini C Mohan, Stephanie A K Angarita, Marissa K Srour, Vicky E Norton, Farnaz Dadmanesh, Armando E Giuliano","doi":"10.1111/tbj.14288","DOIUrl":null,"url":null,"abstract":"For women with breast cancer in whom multiple Oncotype DX® Recurrence Scores (RS) are obtained, RS concordance utilizing current NCCN recommendations has not been evaluated. Patients with two or more RS were identified. RS were stratified by NCCN guidelines and compared for concordance. Twenty-four patients were evaluated. RS concordance varied by tumor type: 100% in the same tumor, 91.7% in multiple ipsilateral tumors, 71.4% in contralateral tumors, and 66.7% in in-breast recurrent tumors. RS concordance for multiple assays in the same patient is not high enough to omit Oncotype DX® testing for each tumor.","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"27 11","pages":"828-831"},"PeriodicalIF":1.9000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/tbj.14288","citationCount":"0","resultStr":"{\"title\":\"Comparison of multiple oncotype DX® from the same patient.\",\"authors\":\"Ashley D Marumoto, Srivarshini C Mohan, Stephanie A K Angarita, Marissa K Srour, Vicky E Norton, Farnaz Dadmanesh, Armando E Giuliano\",\"doi\":\"10.1111/tbj.14288\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"For women with breast cancer in whom multiple Oncotype DX® Recurrence Scores (RS) are obtained, RS concordance utilizing current NCCN recommendations has not been evaluated. Patients with two or more RS were identified. RS were stratified by NCCN guidelines and compared for concordance. Twenty-four patients were evaluated. RS concordance varied by tumor type: 100% in the same tumor, 91.7% in multiple ipsilateral tumors, 71.4% in contralateral tumors, and 66.7% in in-breast recurrent tumors. RS concordance for multiple assays in the same patient is not high enough to omit Oncotype DX® testing for each tumor.\",\"PeriodicalId\":56326,\"journal\":{\"name\":\"Breast Journal\",\"volume\":\"27 11\",\"pages\":\"828-831\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2021-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1111/tbj.14288\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/tbj.14288\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/9/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/tbj.14288","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

对于获得多个Oncotype DX®复发评分(RS)的乳腺癌妇女，尚未评估采用当前NCCN建议的RS一致性。确定了两种或两种以上的RS患者。按NCCN指南对RS进行分层，并比较一致性。对24例患者进行了评估。RS一致性随肿瘤类型的不同而不同:同一肿瘤为100%，多发性同侧肿瘤为91.7%，对侧肿瘤为71.4%，乳腺内复发肿瘤为66.7%。RS一致性对同一患者的多次测定不足以省略Oncotype DX®检测每个肿瘤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Comparison of multiple oncotype DX^® from the same patient.

For women with breast cancer in whom multiple Oncotype DX^® Recurrence Scores (RS) are obtained, RS concordance utilizing current NCCN recommendations has not been evaluated. Patients with two or more RS were identified. RS were stratified by NCCN guidelines and compared for concordance. Twenty-four patients were evaluated. RS concordance varied by tumor type: 100% in the same tumor, 91.7% in multiple ipsilateral tumors, 71.4% in contralateral tumors, and 66.7% in in-breast recurrent tumors. RS concordance for multiple assays in the same patient is not high enough to omit Oncotype DX^® testing for each tumor.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Breast Journal 医学-妇产科学

CiteScore

4.00

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： The Breast Journal is the first comprehensive, multidisciplinary source devoted exclusively to all facets of research, diagnosis, and treatment of breast disease. The Breast Journal encompasses the latest news and technologies from the many medical specialties concerned with breast disease care in order to address the disease within the context of an integrated breast health care. This editorial philosophy recognizes the special social, sexual, and psychological considerations that distinguish cancer, and breast cancer in particular, from other serious diseases. Topics specifically within the scope of The Breast Journal include: Risk Factors Prevention Early Detection Diagnosis and Therapy Psychological Issues Quality of Life Biology of Breast Cancer.